xRead - September 2022

Wise et al.

Page 361

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

AE = adverse effects; AR = allergic rhinitis; ARIA = Allergic Rhinitis and its Impact of Asthma; CNS = central nervous system; DES = Daytime Eye Symptoms; DNS = Daytime Nasal Symptoms; DSSm = mean Daily Symptom Score; DTSSm = mean Total Daily Symptom Score; EAACI = European Academy of Allergy and Clinical Immunology; ESS = Epworth Sleepiness Scale; H 1 = histamine receptor H 1 ; LOE = level of evidence; PAR = perennial allergic rhinitis; QOL = quality of life; QT = measure of time between the onset of ventricular depolarization and completion of ventricular repolarization; RDBCT = randomized double-blind controlled trial; RQLQ = Rhinoconjunctivitis Quality of Life Questionnaire; SAR = seasonal allergic rhinitis; SR = systematic review; TASS = Total Asthma Symptom Score; TNNSS = Total Non-Nasal Symptom Score; TNSS = Total Nasal Symptom Score; TSS = Total Symptom Score; PNIF = peak nasal inspiratory flow; TSSC = Total Symptom Severity Complex.

Study Year LOE Study design Study groups Clinical endpoint Conclusion Bachert & van Cauwenberge 1183 2007 1a SR Desloratadine TSS, TNSS, TNNSS, PNIF, for analysis analysis Desloratadine is well tolerated and efficacious for intermittent and persistent AR with reductions in congestion, TSS, TNSS, and TNNSS, with improved QOL. Desloratadine TSS, TNSS, nasal airflow Reduction in TSS, TNSS, and improved nasal airflow. Canonica et al. 1184 2007 1a SR and meta intermittent/persistent SAR/PAR

Patou et al. 1185 2006 1a SR and meta Levocetirizine Nasal obstruction Improved nasal obstruction under artificial and natural allergen exposure. Schenkel 1186 2006 1a SR Desloratadine Morning symptoms, TSS, TNSS, TNNSS Desloratadine improves TSS and improved QOL in patients with SAR/PAR. 24-hour action makes it effective in controlling morning symptoms. Hore et al. 1187 2005 1a SR of RDBCT H 1 antihistamine vs placebo Nasal obstruction Oral H 1 antihistamines improve nasal obstruction by 22% over placebo. Passalacqua & Canonica 1188 2005 1a SR Levocetirizine; desloratadine Nasal symptoms, wheal-flare response, QOL, TSS Bousquet et al. 1170 2004 1a SR with consensus statement Desloratadine ARIA/EAACI criteria efficacy, safety, pharmacology

Improved QOL and TSS for SAR/PAR. Levocetirizine has a faster onset.

Desloratadine is recommended for treating patients with AR.

Greisner 1189 2004 1a SR Cetirizine; desloratadine; fexofenadine; loratadine Onset of action Inconsistent results. Onset of action is dependent on how it is defined and measured. Limon & Kockler 1190 2003 1a SR Desloratadine TSS, TNSS, TNNSS, nasal congestion, nasal airflow, TASS for SAR/PAR Bojkowski et al. 1191 1989 1a SR Acrivastine (40 studies reviewed) Rhinoconjunctivitis symptoms, nasal congestion, adverse events, drowsiness, CNS depression for SAR/PAR

Desloratadine is a safe and efficacious for patients with SAR/ PAR. Improved TSS, TNSS, and TNNSS, TASS, nasal congestion. Nasal congestion was excluded in the PAR group.

Newer-generation oral H1 antihistamine acrivastine has excellent efficacy for patients with SAR/PAR. Improved nasal congestion. Small increase in drowsiness over terfenadine. No CNS depression found.

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.